The European respiratory journal
Long-term efficacy but rare sustained remission: Individual-level five-year stability in anti-IL5/Rα biologic therapy response for severe asthma.
Kjell Erik Julius Håkansson, Susanne Hansen, Marianne Baastrup Soendergaard, Anna von Bülow, Ole Hilberg, Barbara Bonnesen, Claus Rikard Johnsen, Sofie Lock-Johansson, Lycely Dongo, Maria Bisgaard Borup, Roxana Vijdea, Linda Makowska Rasmussen, Johannes Martin Schmid, Charlotte Suppli Ulrik, Celeste Porsbjerg
Published: 202510.1183/13993003.00926-2025
Abstract
BACKGROUND: For a decade, anti-Interleukin 5/Receptor alpha (IL5/Rα) has been available for severe asthma, with marked reductions in exacerbation rates and maintenance oral corticosteroid (mOCS) burden. However, little is known about the long-term, r…
Preview only. Read the full abstract at the source